EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of Nirmatrelvir Entry into Pulmonary Lining Fluid in Patients with COVID‐19: A Unique Perspective to Explore and Understand the Target Plasma Concentration of 292 ng/mL in Antiviral Activity

Wenjing Zhang iD, Lin Xia, Zhilong Yuan, Yang Jiao, Zhuo Wang

Immunity, Inflammation and Disease · 2024

DOI: 10.1002/iid3.70075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Wenjing Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, COVID-19 Drug Treatment, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the Shanghai "Rising Stars of Medical Talents Youth Development Program-Youth Medical Talents," Clinical Pharmacist Program (SHWSRS….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Currently, the applicant has chosen a target plasma trough concentration for nirmatrelvir, which is adjusted to 292 ng/mL based on the drug's molecular weight (499.54 Daltons), its binding to human plasma proteins (69%), and the in vitro antiviral EC 90 value (181 nM). However, the current exposure‐effect relationships (ER) analysis of viral load in patients enrolled in the EPIC‐HR study has not revealed clinically significant trends in the ER. Given that the lungs are the primary site of COVID‐19 infection, we aim to further understand this exposure relationship by exploring and analyzing the penetration characteristics of nirmatrelvir in the lungs.

Objectives

To explore and understand the target plasma concentration of 292 ng/mL in antiviral activity.

Methods

We identified all critically ill patients with coronavirus disease 2019 who received nirmatrelvir/ritonavir treatment in the respiratory intensive care unit of Changhai hospital between January 2023 and October 2023. Samples of plasma and bronchoalveolar lavage fluid were obtained at pre‐dose trough concentrations after administration of nirmatrelvir (NMV). The relationship between NMV levels in plasma and the epithelial lining fluid (ELF) was assessed by determining concentrations of NMV.

Results

There was a significant relationship between NMV levels in plasma and ELF (ELF = 0.4976*PLASMA‐ 204; R = 0.96), with a correlation whose slope (0.4976) suggested that the blood‐to‐ELF ratio of drug penetration was 2:1. A negative value from the equation indicates that NMV requires to reach baseline concentration to penetrate the ELF.

Conclusions

The relationship between NMV levels in plasma and ELF with low permeability and a negative baseline value suggests that the target plasma concentration of 292 ng/mL is insufficient for antiviral activity. This study provides a unique perspective to explore and understand no clinically meaningful trend of exposure‐response relationships in patients enrolled in EPIC‐HR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2COVID-19 Drug TreatmentCOVID-19Bronchoalveolar Lavage FluidHumansMaleMiddle AgedFemaleAgedLungRitonavirAdultViral LoadIndazoles

Stichwörter der Autor:innen

COVID‐19concentrationhuman epithelial lining fluidnirmatrelvir

Substanzen

Antiviral AgentsRitonavirIndazoles

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
  • School of Pharmacy, Bengbu Medical University, Bengbu, China.
  • Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China.

ORCID-Profile: Wenjing Zhang

Förderung

  • This work was supported by the Shanghai "Rising Stars of Medical Talents Youth Development Program-Youth Medical Talents," Clinical Pharmacist Program (SHWSRS…

Zitieren

APA

Zhang, W., Xia, L., Yuan, Z., Jiao, Y., & Wang, Z. (2024). Analysis of Nirmatrelvir Entry into Pulmonary Lining Fluid in Patients with COVID‐19: A Unique Perspective to Explore and Understand the Target Plasma Concentration of 292 ng/mL in Antiviral Activity. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70075

Vancouver

Zhang W, Xia L, Yuan Z, Jiao Y, Wang Z. Analysis of Nirmatrelvir Entry into Pulmonary Lining Fluid in Patients with COVID‐19: A Unique Perspective to Explore and Understand the Target Plasma Concentration of 292 ng/mL in Antiviral Activity. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.70075

BibTeX
@article{Zhang2024,
  author = {Zhang, Wenjing and Xia, Lin and Yuan, Zhilong and Jiao, Yang and Wang, Zhuo},
  title = {Analysis of Nirmatrelvir Entry into Pulmonary Lining Fluid in Patients with COVID‐19: A Unique Perspective to Explore and Understand the Target Plasma Concentration of 292 ng/mL in Antiviral Activity},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  doi = {10.1002/iid3.70075}
}
Kostenlos starten →